Annual Report

Overview

The report describes Marinomed's 2024 restructuring and creditor agreement, the sale of the Carragelose portfolio to Unither Pharmaceuticals, and the continued focus on the Marinosolv platform. It also reports 100% renewable electricity coverage for the first time, an average workforce of 42 FTEs with 47 total employees, and a Scope 1 carbon-neutrality target for 2030.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services